METHODS OF TREATING AND/OR PREVENTING BEDSORES USING NABILONE

Abstract

Compositions for treating bedsores and methods for treating bedsores are provided. The compositions include a therapeutically effective amount of nabilone and may be formulated for oral or topical administration. The composition may further include a second therapeutic agent such as antifungal agent, steroid, antibiotic, analgesic, and combinations thereof.

Claims

1. A method of treating bedsores comprising administering to a patient an effective amount of nabilone.

2. The method of claim 1, wherein the nabilone is administered orally.

3. The method of claim 1, wherein the nabilone is administered topically.

4. A composition for treating bedsores comprising a therapeutically effective amount of nabilone.

5. The composition of claim 4, wherein the composition is formulated for oral administration.

6. The composition of claim 4, wherein the composition is formulated for topical administration.

7. The composition of claim 6, wherein the composition is formulated as a gel, salve, foam or cream.

8. The composition of claim 6 or 7, wherein the composition comprises a second therapeutic agent.

9. The composition of claim 8, wherein the second therapeutic is selected from the group consisting of antifungal agent, steroid, antibiotic, analgesic, and combinations thereof.

10. A wound dressing for treatment of bedsores comprising a wound dressing and the composition of any one of claims 4 to 9.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0011] Synthetic cannabindiols such as nabilone are provided for the administration orally or topically for the treatment and/or prevention of bedsores.

[0012] Compositions for treatment and/or prevention of bedsores include nabilone as an active agent and may include additional therapeutic agents and/or carriers. Additional therapeutic agents include antifungal agents, steroids, antibiotics, analgesics, and combinations thereof. In some embodiments, the topical composition may also include components to facilitate absorption and/or carriers.

[0013] To gain a better understanding of the invention described herein, the following examples are set forth. It will be understood that these examples are intended to describe illustrative embodiments of the invention and are not intended to limit the scope of the invention in any way.

EXAMPLES

[0014] Patients with dementia having agitation were treated orally at a dose of 0.5 mg nabilone twice a day initially and then going up to a total of 2 mg per day to reduce agitation. A positive clinical side effect of this treatment was that there was a perceived reduction in the number and/or severity of bedsores in those who we were treated. It was further observed that in those patients who did have bedsores, the bedsores appeared to heal faster. The number of patients where this effect was observed was six. The perceived impact on healing was significant with healing times varying between 3-6 weeks for small sores. No large sores were observed in treated patients.

[0015] Although the invention has been described with reference to certain specific embodiments, various modifications thereof will be apparent to those skilled in the art without departing from the spirit and scope of the invention. All such modifications as would be apparent to one skilled in the art are intended to be included within the scope of the following claims.